Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib Plus Obinutuzumab vs. Cladribine Plus Rituximab in Previously Untreated Hairy Cell Leukemia
NCT06561360Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, obinutuzumab in hairy cell leukemia (HCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2024; status: recruiting.
02
Drugs
vemurafenibobinutuzumab
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT06561360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561360.